TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02844881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 850 mg p.o. qd every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MASCT
Description: Dendritic cells(DC) loaded with 17 antigens ih day 8, cytotoxic T lymphocytes ( CTL) induced by DC IV day 21-28, every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
Study: NCT00887679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 10-20 mg/day oral of Escitalopram for 6-weeks. Escitalopram flexible dose (10-20 mg/day). A forced escalation schedule of escitalopram was used to titrate it to the maximum tolerated dose. Drug was discontinued at the end of the study.
Study: NCT04494581

Intervention type: OTHER
Intervention: questionnaire
Description: Questionnaire survey

Intervention type: OTHER
Intervention: questionnaire
Description: Questionnaire survey
Study: NCT02573454

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: App assignment
Description: Under-active undergraduates are assigned to use a GPS exercise app that is prosocial (i.e., allows the user to raise money for charities) or personal (does not allow the user to raise money for charities) in nature

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App assignment
Description: Under-active undergraduates are assigned to use a GPS exercise app that is prosocial (i.e., allows the user to raise money for charities) or personal (does not allow the user to raise money for charities) in nature
Study: NCT02683941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide (Autogel formulation)
Description: 120mg every 28 days until disease progression, death, or unacceptable toxicity

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution 0.9% administered via deep subcutaneous injection every 28 days until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: Best Supportive Care is best available therapy at the choice of the investigator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: Best Supportive Care is best available therapy at the choice of the investigator
Study: NCT02475174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Without upper limb elevation
Description: Lymphatic drainage without elevation of the upper limb.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper limb elevation to 30º
Description: Lymphatic drainage with elevation of the upper limb to 30º.
Study: NCT04359875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone-call screening and management by a medical student/general practitioner tandem
Description: Systematic phone contact of the patient by a medical student, under the indirect supervision of the general practitioner. This phone contact will be standardized with 3 questions to ask to the patient:~* How are you doing? (with a Likert scale from 1=very bad to 10=very well)~* Would you have made an appointment with your general practitioner if there had not been COVID19 epidemic and containment?~* Would you like an appointment with your doctor and / or has your doctor ever contacted you? In view of the answers to these 3 questions, the general practitioner will decide whether it is necessary to propose a consultation or a teleconsultation to the patient, taking into account his/her medical background.
Study: NCT00892723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZX100 Drug Product
Description: Subjects were administered AZX100 0.3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZX100 Drug Product
Description: Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
Study: NCT01776424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Tablet, 2.5 mg, twice daily, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Tablet, 5 mg, twice daily, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Tablet, 100 mg, once daily, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Tablet, 100 mg, once daily, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin placebo
Description: Aspirin matching placebo, once daily, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban placebo
Description: Rivaroxaban matching placebo, twice daily, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Tablet, 40 mg, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Tablet, 40 mg, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Tablet, 40 mg, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole placebo
Description: Pantoprazole matching placebo, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole placebo
Description: Pantoprazole matching placebo, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole placebo
Description: Pantoprazole matching placebo, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole placebo
Study: NCT01060826

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fisiologic serum
Description: 250 microgramos bolus intravenous during 3 minutes and continuous infusion for 4 hours after endoscopic procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatostatin, intravenous bolus
Description: 250 microgramos bolus intravenous in 3 minutes and continuous infusion for 4 hours after endoscopic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatostatin
Description: Intravenous bolus 250 micrograms
Study: NCT02347033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline will be prescribed by the patients' GP, starting at 25mg daily for 1-2 weeks and increasing to 50mg daily if tolerated. The GP should review the patient within the first 2 weeks, checking for acceptability, concordance and any side-effects, with further reviews at 6 and 12 weeks. We expect the usual treatment dose to be 50 to 100mg daily, although some may require 150mg.~We will suggest that the GPs use their usual procedures to review the patient's progress, asking about and noting functional change as well as clinical improvement. Minimal improvement after 12 weeks at a maximal tolerated dose should prompt consideration of change of treatment. If there has been an adequate therapeutic benefit there should be further review at 26 and 52 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Description: CBT will consist of 14 (+ / - 2) weekly 50-minute sessions and will cover 6 treatment modules: psychoeducation and worry awareness training; re-evaluation of the usefulness of worry; uncertainty recognition and behavioural exposure; problem-solving training; written exposure; and relapse prevention.~Sessions will be digitally recorded and a random 10% assessed for quality (fidelity to the manual and therapist competence) by an independent external assessor according to pre-specified criteria. Patient consent for this will be obtained as part of obtaining informed consent.
Study: NCT00338364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAT
Description: Coping and Distraction Intervention
Study: NCT02913729

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: partial breast irradiation
Description: irradiation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: partial breast irradiation
Description: irradiation
Study: NCT01138579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FBTA05
Study: NCT04496063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Intravenous induction (6mg/kg) followed by Ustekinumab subcutaneous 90mg every 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous followed by Placebo subcutaneous every 8 weeks
Study: NCT01560689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide/formoterol
Description: 800 µg/j twice a day, every day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice a day, every day
Study: NCT04066790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib 400 mg taken orally everyday, every 3 weeks, for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Nab-paclitaxel 100mg/m2 by intravenous (IV) infusion on day1, day8 and day15, every 3 weeks, for 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-Paclitaxel
Description: Nab-paclitaxel 100mg/m2 by intravenous (IV) infusion on day1, day8 and day15, every 3 weeks, for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 9, followed by 6 mg/kg for remaining cycles till completion of 1 year trastuzumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 9, followed by 6 mg/kg for remaining cycles till completion of 1 year trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC chemotherapy
Description: epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks 4 cycles (Cycles 5-8)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC chemotherapy
Description: epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks 4 cycles (Cycles 5-8)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
Study: NCT00046085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Family Education
Description: Families were provided with private, secure access to the website, which features family-to-family chat capabilities, video lectures on the management of schizophrenia, written materials on important issues in schizophrenia management, professionally facilitated online discussions of the material, and additional resource links.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Customary care
Description: Participants received care as usual.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Customary care
Description: Participants received care as usual.
Study: NCT01487031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Patients randomized to receive music therapy will receive 2 sessions of live music therapy, at least 48 hours apart, from a Music Therapist-Board Certified (MT-BC, certified through the Certification Board for Music Therapists) in their room

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No music therapy
Description: Those patients randomized to standard therapy (no music therapy) are allowed to listen to music; however they will not receive interactive music therapy from a certified therapist.
Study: NCT03752099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERU-111
Description: VERU-111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERU-111
Description: VERU-111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERU-111
Description: VERU-111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERU-111
Description: VERU-111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERU-111
Description: VERU-111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERU-111
Description: VERU-111
Study: NCT01087931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Single application of 10ml of bupivacaine 0.5% into the iliac crest bone harvest surgical site.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline 0.9%, 10ml, single application directly into iliac crest bone harvest surgical site.
Study: NCT03706339

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline arm group
Description: 110 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the placental bed during Cesarean section

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous tranexamic acid
Description: 1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the pelvic bed during cesarean section

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid
Description: 2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 120 ml normal saline applied on the pelvic bed during cesarean section plus110 ml normal saline IV just before skin incision
Study: NCT01207726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02623881

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical pessary
Description: Arabin (cervical pessary) will be inserted at 16-22 weeks and removed at 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal progesterone
Description: Vaginal progesterone (Cyclogest 400 mg) once a day will be used, from 16-22 to 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
Study: NCT00459160

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative Hypotensive Resuscitation
Description: Patients will have a target minimum MAP of 50 for the case
Study: NCT01091753

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valsaltan, amlodipine
Description: nti hypertensive medication time (nocturnal administration vs morning administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsaltan, amlodipine
Description: nti hypertensive medication time (nocturnal administration vs morning administration
Study: NCT01673568

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ETO garments
Description: patients wearing abdominal binder for 7 days postoperatively
Study: NCT04156230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]GP1 positron emission tomography/computed tomography
Description: A radioactive dose of 250 MBq of the study drug with a total quantity of ≤ 10 µg will be administered as slow intravenous bolus injection over up to 60 seconds. PET/CT examinations will be performed at 120 ± 15 min after the administration of \[18F\]GP1.
Study: NCT03090815

Intervention type: GENETIC
Intervention: Sequencing of ctDNA in plasma
Description: Sequencing of ctDNA in plasma

Intervention type: GENETIC
Intervention: Sequencing of ctDNA in plasma
Description: Sequencing of ctDNA in plasma

Intervention type: GENETIC
Intervention: Sequencing of ctDNA in plasma
Description: Sequencing of ctDNA in plasma
Study: NCT03740997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optison
Description: Optison is administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optison
Description: Optison is administered intravenously
Study: NCT02496520

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cells
Description: vaccines with dendritic cells pulsed with tumor lysate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery as needed by the patient´s tumor and stage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy as needed by the patient´s tumor and stage

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy as needed by the patient´s tumor and stage
Study: NCT02577757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Description: MRI
Study: NCT03765411

Intervention type: PROCEDURE
Intervention: Proctectomy
Description: Resection of the rectum

Intervention type: PROCEDURE
Intervention: Proctectomy
Description: Resection of the rectum

Intervention type: PROCEDURE
Intervention: Proctectomy
Description: Resection of the rectum
Study: NCT04823715

Intervention type: OTHER
Intervention: TACE + hypofractionated EBRT
Description: One cure of doxorubicin or DC Beads transarterial chemoembolization by a highly experienced interventional radiologist, followed 1 to 4 weeks later by hypofractionated external beam radiation therapy up to a total dose of 45-60 Gy, 3 Gy per fraction, 5 fractions per week, for an overall treatment time of 3 to 4 weeks.

Intervention type: PROCEDURE
Intervention: Surgical resection
Description: Surgical resection by open-laparotomy or laparoscopy of hepatocellular carcinoma by a highly experienced liver surgeon
Study: NCT02020629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Description: Lixisenatide is given for 6 weeks whereafter a hypoglycemia clamp is undertaken
Study: NCT00888433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation (Symplicity® Renal Denervation System)
Description: Catheter-based renal denervation
Study: NCT00755703

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic Influenza Vaccine
Description: Undetermined

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic Influenza Vaccine
Description: Undetermined

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic Influenza Vaccine
Description: Undetermined

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04237766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: The intervention will consist of the visualization of the movement through the Mirror Therapy application, or through the reproduction of an immersive 360º video emitted on a mobile device and visualized with virtual reality glasses.~The movements observed with both technologies will be the same. The knee extension and dorsal ankle flexion movements (quadriceps and triceps sural), together with the elbow flexion (elbow flexors) will be the movements to be performed, based on their functional need (ambulation and feeding, respectively).
Study: NCT00604812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate (5 mg)
Description: A single dose of rizatriptan 5 mg administered on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate (5 mg)
Description: A single dose of rizatriptan 5 mg administered on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate (10 mg)
Description: A single dose of rizatriptan 10 mg administered on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rizatriptan benzoate (10 mg)
Description: A single dose of rizatriptan 10 mg administered on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rizatriptan 5 mg Placebo
Description: A single dose of rizatriptan 5 mg placebo administered on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rizatriptan 5 mg Placebo
Description: A single dose of rizatriptan 5 mg placebo administered on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rizatriptan 10 mg Placebo
Description: A single dose of rizatriptan 10 mg placebo administered on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rizatriptan 10 mg Placebo
Description: A single dose of rizatriptan 10 mg placebo administered on Day 1.